ERBB2 and breast carcinoma: Interestingly, a recent large-scale study involving 4,769 HER2-positive breast cancer patients revealed that 3.3% of patients experienced cardiotoxicity during dual anti-HER2 therapy (de Azambuja et al., 2023).